July 1, 2004Current Medicinal Chemistry - Cardiovascular & Hematological Agents

Platelet Glycoprotein IIb / IIIa Inhibition and its Clinical Use

Q: What is the clinical evidence from this study?

Study design: Review. Population: Cardiovascular, cerebrovascular and peripheral vascular diseases and acute coronary syndromes. Intervention: Glycoprotein IIb/IIIa antagonists.

View Full Paper

Ask AI

Bookmark

Key result

This review summarizes the molecular biology, development, clinical trials, adverse effects, and future directions of glycoprotein IIb/IIIa antagonists for cardiovascular diseases.

Design

Review

Authors

FHFengyang HuangUniversity of Science and Technology of China EHEnrique HongInstituto de Estudios Avanzados

Discussion

Member takes

Implication

Guides cautious GP IIb/IIIa use in ACS; leaves open their role amid newer agents.

Structured PICO

Intervention

Glycoprotein IIb/IIIa antagonists (abciximab, eptifibatide, tirofiban)

This review summarizes the molecular biology, clinical development, and adverse effects of glycoprotein IIb/IIIa antagonists in cardiovascular disease.

Cite This Study

Huang et al. (2004) conducted a review in Cardiovascular, cerebrovascular and peripheral vascular diseases and acute coronary syndromes. Glycoprotein IIb/IIIa antagonists was evaluated. This review summarizes the molecular biology, development, clinical trials, adverse effects, and future directions of glycoprotein IIb/IIIa antagonists for cardiovascular diseases.

synapsesocial.com/papers/6a93bd72603bc226d57c1df9 https://doi.org/10.2174/1568016043356309

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

Platelet Glycoprotein IIb / IIIa Inhibition and its Clinical Use

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Topics

Platelet Glycoprotein IIb / IIIa Inhibition and its Clinical Use

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider